FY2025 Earnings Estimate for BDTX Issued By HC Wainwright

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Research analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for Black Diamond Therapeutics in a research report issued on Wednesday, November 12th. HC Wainwright analyst R. Burns now forecasts that the company will earn $0.46 per share for the year, up from their previous forecast of $0.33. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q4 2025 earnings at ($0.19) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($0.83) EPS.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07.

Several other analysts also recently weighed in on BDTX. Guggenheim began coverage on shares of Black Diamond Therapeutics in a research note on Wednesday, September 3rd. They issued a “buy” rating and a $8.00 price target for the company. Zacks Research cut Black Diamond Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 10th. Wall Street Zen cut Black Diamond Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Stifel Nicolaus started coverage on Black Diamond Therapeutics in a research note on Wednesday, October 15th. They issued a “buy” rating and a $8.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Black Diamond Therapeutics in a report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $9.60.

Black Diamond Therapeutics Stock Down 1.9%

Shares of NASDAQ BDTX traded down $0.09 during mid-day trading on Friday, reaching $4.41. 422,990 shares of the company were exchanged, compared to its average volume of 1,690,501. Black Diamond Therapeutics has a 52 week low of $1.20 and a 52 week high of $4.94. The company’s 50 day moving average price is $3.74 and its 200 day moving average price is $2.90. The stock has a market capitalization of $250.95 million, a PE ratio of 12.29 and a beta of 3.12.

Institutional Investors Weigh In On Black Diamond Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Black Diamond Therapeutics by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 2,188,857 shares of the company’s stock worth $8,296,000 after acquiring an additional 85,825 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Black Diamond Therapeutics by 549.2% in the third quarter. Arrowstreet Capital Limited Partnership now owns 896,853 shares of the company’s stock worth $3,399,000 after purchasing an additional 758,709 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Black Diamond Therapeutics during the second quarter valued at approximately $1,830,000. UBS Group AG grew its stake in shares of Black Diamond Therapeutics by 100.3% during the third quarter. UBS Group AG now owns 628,416 shares of the company’s stock valued at $2,382,000 after buying an additional 314,716 shares during the last quarter. Finally, AWM Investment Company Inc. bought a new position in shares of Black Diamond Therapeutics during the first quarter valued at approximately $775,000. Institutional investors own 95.47% of the company’s stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.